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SURGICAL ETHICS CHALLENGES
Complying with advance directives in the
operating room
James W. Jones, MD, PhD,a and Laurence B. McCullough, PhDb
An ambulance brings an unconscious 41-year-old man
to the emergency department after an automobile acci-
dent. Emergency computed tomography shows rupture
of the liver, spleen, and superior mesenteric artery. He
is being prepared for surgery when his business partner
arrives with what he claims is the patient’s signed
advance directive, specifying that in the event of cardiac
arrest, the patient wishes that no resuscitative measures
be taken. During surgery, the patient suffers an acute
hypotensive episode and arrests. Your proper response
is which of the following?
A. Do not resuscitate.
B. Resuscitate and continue the operation.
C. Limit your resuscitative efforts to closed chest massage.
D. Consult the business partner.
E. Ignore the advance directive.
B is the most ethically sound option.
The “living will” advance directive is defined by most
statutes and hospital policies as the medical instructions of
a terminally ill or injured patient who can no longer com-
municate his immediate wishes.1 Living wills typically con-
centrate on end-of-life issues, particularly withdrawing or
withholding efforts to sustain a life that cannot be saved or
restored to a functional level acceptable to the patient. They
may conversely express the wish that all available life-
sustaining efforts be fully implemented until death is spon-
taneous. A “terminal illness or injury” is understood to
mean that death is inevitable within a short time regardless
of medical intervention. The living will provisions of ad-
vance directives should not govern physicians’ clinical re-
sponses when the patient’s clinical status does not meet
these criteria.
Though grievously injured, this patient can recover
with timely and competent surgical care. His intraoperative
arrest is a correctable complication of fluid management,
likely not the culminating event of an inevitably terminal
illness or injury. Intraoperative resuscitation maintains ho-
meostasis, and patient recovery in such cases is routine, as
opposed to the overall 15% success rate of cardiopulmonary
resuscitation.2 The patient’s refusal of cardiopulmonary
resuscitation in the advance directive may ethically be un-
derstood to apply in the context of these poor success rates,
which include not just death but survival with a greatly
diminished quality of life. The advance directive’s election
of Choice A, no resuscitation, was very likely formulated
without consideration of functional conditions in the op-
erating room, and would furthermore deny the patient the
benefits for which he was originally brought to the operat-
ing room. Choice B is fully consistent with the goals of
surgery and is a necessary and proper response for a patient
whose condition does not activate the authority of a living
will.
Some ethicists argue that advance directives containing
do-not-resuscitate instructions should be as applicable in-
side the operating room as in the intensive care unit.3
Others have argued that the conditions of surgery blur the
distinctions between resuscitation and maintenance of ho-
meostasis,2 or that many physicians routinely dismiss ad-
vance directives, or that patients seldom understand the
processes of surgical care. Attempting to straddle these
issues by limiting the procedural options of the resuscita-
tion efforts (Choice C) strengthens neither the physician’s
ethical posture nor his clinical effectiveness and is inconsis-
tent with the goals of surgery and conditions under which
the advance directive has clinical authority.
The business partner is not the next of kin and has no
legal standing as a surrogate decision-maker unless he has
been named as an agent in a durable medical power of
attorney. Furthermore, the patient’s own views have been
articulated in the advance directive, which would stand as
the last available expression of his wishes if it otherwise
qualified. Choice D is therefore not available.
Ignoring the advance directive, Choice E, which leg-
end holds is a common tactic among physicians who find
such instructions odious, is not acceptable. Notwithstand-
ing, the surgeon is obligated to evaluate the directive in
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light of the patient’s clinical condition to establish its
pertinence. As noted, the qualities necessary to establish the
authority of an advance directive, ie, a terminal condition
not susceptible to reversal with medical care, are not
present, and the physician is not governed by the terms of
the document. In such cases, the chart should reflect why
the surgeon is not implementing the directive.
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